Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

Gloved hands holding petri dish
Earlier this month, the results of the first head-to-head biological study, VARSITY, were released at the 2019 European Crohn’s and Colitis Organization (ECCO) Congress. This international event brings together thousands of researchers and stakeholders from around the world to advance research and care.

VARSITY was a population-based trial that studied 767 patients with moderate to severe ulcerative colitis across 37 countries who had not responded to conventional therapy. Researchers found a difference between the treatments across members of this group, where a larger percent of patients treated with vedolizumab (Entyvio®) fared better compared to adalimumab (Humira®). 

It is important to remember that everyone experiences Crohn’s and colitis differently. What works for one patient may not work for another—and only the patient themselves and their doctor are able to determine the best treatment plan for the patient’s unique situation. 

Ultimately, more research allows these patient-doctor partnerships to make informed decisions, so we encourage those affected by Crohn’s and colitis to continue reading and learning about different treatment options.

To find out more about the results of the VARSITY trial, click here.

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest